Assessment of safety and efficacy of Kabasura Kudineer in mild to moderate COVID-19

Assessment of safety and efficacy of Kabasura Kudineer as an add-on therapy in mild to moderate COVID-19. - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/08/026985

Enrollment

126

Registered

2020-08-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Kabasura Kudineer along with standard treatment: Kabasura kudineer 60ml twice daily before food for 7 days along with standard treatment Control Intervention1: Standard treatment as per

Eligibility

Inclusion criteria

Inclusion criteria: a.COVID-19 positive patients with mild to moderate disease. b.Males and females aged between 18 and 60 years who are admitted in Chettinad Hospital and Research Institute c.Patients willing to give written informed consent.

Exclusion criteria

Exclusion criteria: a.Patients Suffering from Chronic diseases- hepatic, renal, Hypertension and Diabetes mellitus b.Pregnancy & lactation c. Severe COVID-19

Design outcomes

Primary

Measure	Time frame
1.Time to Negative conversion of SARS CoV-2 2.Time to symptom resolution 3.Reduction in Viral load (0,4,7 days) Timepoint: 4,7 days	—

Secondary

Measure	Time frame
1. Progression to severe ARDS 2. Adverse effects/eventsTimepoint: 7 days	—

Countries

India

Contacts

Public ContactDr Ruckmani A

Chettinad Hospital and Research Institute

ruckmani.nirmal@gmail.com9500102346

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026